RITUKSIMAB V LEChENII KhRONIChESKOGO LIMFOLEYKOZA: REFERATIVNYY OBZOR


Cite item

Full Text

Abstract

Рассматриваются современные подходы к лечению хронического лимфолейкоза (ХЛЛ), обосновывается применение при ХЛЛ ритуксимаба - моноклонального антитела к CD20-рецепторам. Представлены результаты рандомизированных клинических исследований, посвященных оценке эффективности ритуксимаба при ХЛЛ. На их основании был сделан вывод о превосходстве иммунохимиотерапии с ритуксимабом над химиотерапией в лечении больных ХЛЛ. Подчеркивается, что золотым стандартом в лечении больных ХЛЛ как в первой, так и во второй линии терапии может считаться режим FCR (флударабин, циклофосфан, ритуксимаб).

About the authors

N B Mikhaylova

References

  1. Sigurdur Y, et al. Improved survival in chronic lymphocytic leukemia in the past decade: a population-based study including 11,179 patients diagnosed between 1973-2003 in Sweden. Haematologica 2009;94(9):1259-65.
  2. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-33.
  3. Almasri NM, Duque RE, Iturraspe J, et al. Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia. Am J Hematol 1992;40:259-63.
  4. Byrd JC, Grever MR, Davis B. Phase I/II Study of Thrice-Weekly Rituximab in ChronicLymphocytic Leukemia/Small lymphocytic Lymphoma: A Feasible and Active Regimen. Oncol 2000;14:abstr. 3114.
  5. O'Brien S, Kantarjian H, Thomas D, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001;19:2165-70.
  6. Di Gaetano N, Xiao Y, Erba E, et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 2001;114:800-09.
  7. Alas S, Emmanouilides C, Bonavida B. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res 2001;7:709-23.
  8. Byrd JC, Peterson L, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B9712 (CALGB 9712). Blоod 2003;101:6-14.
  9. Kеating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079-88.
  10. Тam CS, O'Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008;112:975-80.
  11. Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005;105:49-53.
  12. Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006;107:885-91.
  13. Flinn IW, Kumm E, Grever MR, et al. Fludarabine and cyclophosphamide produces a higher complete response rate and more durable remissions than fudarabine in patients with previously untreated CLL: Intergroup trial E2997. Blood 2004;104:139a, abstr. 475.
  14. Catovsky D, Richards S, Hillmen P. Early results from LRF CLL4: a UK multicenter randomized trial. Blood 2005;106:abstr. 716.
  15. Hallec M, Fingerle-Rowson G, Fink A-M, et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL). Blood 2008;112:abstr. 325.
  16. Lamanna N, Kalaycio M, Maslak P, et al. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 2006;24:1575-81.
  17. Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005;23:4070-78.
  18. Thomas et al, in: Cheson (ed.). Chronic lymphoid leukemias. M. Dekker 2001;275-335.
  19. Robak T, Moiseev S, Dmoszynska A, et al. Rituximab, fludarabine, and cyclophosphamide (R-FC) prolongs progression free survival in relapsed or refractory chronic lymphocytic leukemia (CLL) compared with FC alone: final resultsfrom the international randomized phase III REACH Trial. Blood 2008;112:abstr. 1.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies